Research and Development Expenses Breakdown: Merck & Co., Inc. vs Wave Life Sciences Ltd.

Merck vs. Wave: A Decade of R&D Investment

__timestampMerck & Co., Inc.Wave Life Sciences Ltd.
Wednesday, January 1, 201471800000002395000
Thursday, January 1, 201567040000009057000
Friday, January 1, 2016719400000040818000
Sunday, January 1, 2017998200000079309000
Monday, January 1, 20189752000000134428000
Tuesday, January 1, 20199872000000175431000
Wednesday, January 1, 202013397000000130944000
Friday, January 1, 202112245000000121875000
Saturday, January 1, 202213548000000115856000
Sunday, January 1, 202330531000000130009000
Loading chart...

Data in motion

A Decade of Innovation: R&D Spending in Pharmaceuticals

In the ever-evolving world of pharmaceuticals, research and development (R&D) is the lifeblood of innovation. Over the past decade, Merck & Co., Inc. has consistently demonstrated its commitment to advancing medical science, with R&D expenses peaking at a staggering $30.5 billion in 2023, a 330% increase from 2014. This investment underscores Merck's dedication to pioneering new treatments and therapies.

In contrast, Wave Life Sciences Ltd., a smaller player in the industry, has shown a steady increase in R&D spending, reaching $130 million in 2023. While this figure is modest compared to Merck, it represents a significant growth from just $2.4 million in 2014, highlighting Wave's ambition to carve out its niche in the competitive biotech landscape.

This comparison not only reflects the scale of investment required for pharmaceutical innovation but also the diverse strategies companies employ to drive progress.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025